Mallinckrodt divests BioVectra for $250mm as it focuses on specialty brands
- Nanotechnology, Chips, etc.
- Synthesis Technologies, Production Processes
- Large Molecule
- Contract Research, Toxicology Testing-CRO
- Payment Includes Cash
- Full Acquisition
- Includes Earnout
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.